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Previewsbe highly relevant to clinical re-
sistance to conventional cytotoxic chem-
otherapy (Ni Chonghaile et al., 2011).
Moreover, transplantation of human
T-ALL into mice is associated with clonal
evolution that closelymimics the evolution
observed in human patients between
diagnosis and relapse (Clappier et al.,
2011), highlighting the relevance of
this approach to treatment resistance in
humans.
The findings of Blackburn et al. (2014)
have clear potential translational impli-
cations, because they suggest that AKT
activation in T-ALL cells with LPC poten-
tial may be poised to mediate treatment
resistance and relapse. The authors
show that these cells can be effec-
tively targeted by the combination of
dexamethasone and AKT inhibitors,
potentially due to reversal of AKT-
mediated dexamethasone resistance
(Piovan et al., 2013), thus providing an
additional rationale for clinical trialstesting such a strategy in high-risk
T-ALL.ACKNOWLEDGMENTS
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Tumors arise from single cells but become genetically heterogeneous through continuous acquisition of
somatic mutations as they progress. In this issue of Cancer Cell, Klco and colleagues used whole genome
sequence analysis to demonstrate the correlation of genetic clonal architecture with functional heterogeneity
in acute myeloid leukemia.A major tenet of cancer biology is that
tumors are clonal reflecting their origins
from single cells. This is best illustrated
by early seminal cytogenetic studies
demonstrating that all cells of a patient’s
leukemia, for example, may harbor a spe-
cific chromosomal aberration. However,
it has also been recognized for decades
that leukemias and solid tumors are het-
erogeneous in their genetic composition
such that, despite sharing a specific
chromosomal aberration, not all cells of
a given cancer demonstrate a completely
identical cytogenetic profile. This intratu-
moral genetic heterogeneity extends tothe level of individual genes and DNA
mutations as shown by next-generation
sequencing technologies and is fully
expected based on the fact that tumor
(and normal) cells acquire new mutations
with each cell division. At a practical
level, somatically acquired mutations
that accumulate at defined frequencies
can distinguish individual cells or tumor
subclones and serve as a clock to mark
and track their divergence from a com-
mon ancestor cell. The complexity of
clonal architecture has been shown
in hematological malignancies, includ-
ing acute lymphoblastic leukemia (ALL)(Anderson et al., 2011) and acute myeloid
leukemia (AML) (Ding et al., 2012) as well
as other cancer types such as breast
carcinoma (Shah et al., 2009), and is likely
a universal feature of all cancers. It is also
known that subpopulations of cells in
an individual tumor can be morphologi-
cally or functionally distinct, e.g., display
sensitivity or resistance to therapeutic
agents. However, the relationship be-
tween intratumoral genetic heterogeneity
and cancer cell function has not been
well defined. Nevertheless, clonal evolu-
tion has major implications for under-
standing the cellular hierarchies and5, March 17, 2014 ª2014 Elsevier Inc. 265
Figure 1. Functional and Genetic Heterogeneity of Primary AML
A founding AML clone arises with accumulation of a set of acquired ‘‘signature’’ mutations. During tumor
progression, the founding clone evolves into genetically distinct subclones through the acquisition of
new mutations. The complete spectrum of mutations defines morphological and phenotypic properties
of the subclones that correlate with distinct functional characteristics, such as in vitro growth, engraftment
in immune-deficient mice, or relapse in patients.
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Previewsinterrelationships in tumors, as well as the
development and application of targeted
therapies in the rapidly unfolding era of
personalized medicine. In this issue of
Cancer Cell, Klco et al. (2014) explored
the correlation of clonal architecture
with functional heterogeneity in AML.
Rather than a melting pot blend of opera-
tional and genomic diversity, the data
support that AML comprises a salad
bowl of distinct subclones whose func-
tional differences may be genetically
determined (Figure 1).
Whole genome (and capture-based
targeted) sequences were analyzed to
determine the somatic mutations present
in unfractionated bone marrow cells of
patients at presentation with de novo
AML encompassing a range of morpho-
logical and genetic subtypes. The spec-
trum of mutations and their fractional
representation was used to define the
founding clone, from which all leukemic
cells were descended, and also identify
leukemic cell subpopulations possessing
the ‘‘signature’’ variants of the founding
clone as well as additional subclonal
sequence variants that arose during
tumor evolution. Sequence analysis of
single cells purified by cell sorting in266 Cancer Cell 25, March 17, 2014 ª2014 Eseveral AMLs verified the identity of
subclonal genotypes and the allele frac-
tions deduced from unfractionated bone
marrow samples.
The genetically defined subclones
were evaluated under various biological
and experimental conditions. The clonal
architecture present in the bone marrow
was consistently detected in the peri-
pheral blood, indicating no major differ-
ences in trafficking properties among
different AML subclones, unlike the
regional intratumoral and metastatic
variation reported in solid tumors (Navin
et al., 2011). Mutations found in AML
blast cells were often present in morpho-
logically more mature myelomonocytic
cells, demonstrating maintenance of at
least minimal differentiation potential
despite the presence of AML driver genes
that otherwise antagonize maturation.
Somatic mutations in rare peripheral
blood B and T lymphocytes suggested
the acquisition of some mutations in
leukemic multi-potential hematopoietic
stem-progenitor cells or even in pre-
leukemic hematopoietic stem cells con-
sistent with recent observations (Shlush
et al., 2014). In some cases, morphologic
or phenotypic features, as well as in vitrolsevier Inc.growth properties, correlated with distinct
subclones, suggesting functional varia-
tion in differentiation potential that may
be genetically determined.
The in vivo functional heterogeneity
of cells comprising leukemia samples at
disease presentation was interrogated
by transplantation into immune-com-
promized mice. Unexpectedly, none of
the resulting xenografts displayed a
clonal architecture that was identical
to that of the transplanted AML. Rather,
subclones showed variable engraftment
potential, and single subclones generally
predominated in the engrafted mice
despite the presence of multiple sub-
clones in the injected sample. Relapsing
AML subclones were not predicted by
engraftment outcome or by the presence
of recurring AML mutations. Thus, in
many cases, there was no apparent
relationship between the engrafting cells
and the evolutionary hierarchy of the leu-
kemia subclones in the patient. However,
these results should be interpreted with
caution. Although the functional hetero-
geneity among AML clones was clearly
demonstrated, the engrafted subclone
in some cases was dictated by the recip-
ient mouse strain used. This underscores
that xeno-engraftment can be affected by
a variety of technical factors that were not
optimized, such as mouse strain and pre-
conditioning, route of injection, number of
injected cells, and time for engraftment/
disease assessment. The application of
next-generation sequencing techniques
in future studies should illuminate the
relative influence of these various factors
on the clonal compositions and clinical
significance of engrafting leukemia cells.
AML cells capable of engrafting in
xenograft assays, and thus establishing
disease in mice, are operationally defined
as leukemia-initiating cells or leukemia
stem cells (LSCs) (Lapidot et al., 1994).
Previous studies have shown that LSCs
defined by this experimental approach
may be phenotypically heterogeneous
(Goardon et al., 2011). The studies of
Klco et al. (2014) extend this to suggest
that LSCs may also be genetically
heterogeneous. Importantly, the founding
AML clone defined genetically may not
necessarily be the same as the LSC
clone defined functionally by xenotrans-
plantation. This likely reflects that
xeno-transplant models exert selective
growth pressures through the mouse
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Previewsmicroenvironment or lack of immune sys-
tem that are not equivalent to those
encountered by leukemia cells in the
patient. The authors’ results highlight
the clonal and functional diversity of
LSCs and suggest that future studies
should include an integration of genetic
and functional data as part of their
characterization.
The authors correlated the presence
of specific subclones marked by their
respective mutational spectra with func-
tional readouts, but the mutations that
mechanistically account for the observed
functional differences are unknown. It
will be important to define the genetic
(or epigenetic) determinants that underlie
the observed biology, particularly the
genes or pathways that may promote
engraftment in various immune-compro-
mised mouse models and relapse in
patients.
Xenograft models also serve an instru-
mental role in the preclinical stages of
cancer therapeutics development.
Indeed, almost every FDA-approved
anticancer drug in the modern era has
been tested in such models. However,
they are known to have limitations for
predicting clinical responses in solidtumors (Sharpless and Depinho, 2006),
and the results of Klco et al. (2014) under-
score potential constraints of the ap-
proach to evaluate drug efficacy in AML,
although previous studies have demon-
strated their value in predicting early
relapse in ALL (Meyer et al., 2011). Clonal
analysis through whole genome sequenc-
ing provides a powerful approach for
assessing the fidelity of xenografts in
support of ongoing efforts to devise novel
targeted therapeutics directed at the
pathways and mutant factors that sustain
critical functions of founding clones and/
or cancer stem cells.
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In this issue of Cancer Cell, Kool and colleagues reveal clear genetically defined subclasses of the sonic
hedgehog (SHH) subclass of medulloblastoma. This molecular dissection of the SHH subclass is not simply
a cutting-edge advance; the data have profound impact on clinical trial design and decision-making.Twenty years ago, the world health orga-
nization guidelines and revered neuropa-
thologists encouraged us to ‘‘lump’’ any
small round blue cell tumor in the brain
into a single category for the purpose of
clinical trials and therapeutics. The only
way to improve survival in the ‘‘age of
the lumpers’’ was to intensify therapy, sowe collectively brought the kids to the
very edge of life and death. This resulted
in improved survival rates at the expenses
of both short- and long-term toxicity (Ja-
kacki et al., 2012; Packer et al., 2006).
It is now the age of the ‘‘splitters’’. In
the wake of a half dozen outstanding
medulloblastoma genomics papers in2012, Kool et al. (2014, in this issue of
Cancer Cell) now further show us that
there are at least three distinct molecular
subclasses within the sonic hedgehog
(SHH)-driven subclass of medulloblas-
toma. These data create a double-edged
sword, establishing clear responder hy-
potheses while revealing that, as we5, March 17, 2014 ª2014 Elsevier Inc. 267
